Concepedia
Statistics
Publications
25
Citations
2.7K
H-Index
23
Active since
1992
Affiliations
AstraZeneca (United Kingdom)(Current)
AstraZeneca (Singapore)
AstraZeneca (France)
Neil H. James is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and apoptosis.
Publications per year
1992–2021
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text
Medicine, Oncology, Pharmacology +17
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 334 citations · Full text
Medicine, Oncology, Radiation Oncology +17
Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Neil R. Smith, Dawn Baker, Neil H. James et al. · Clinical Cancer Research · 2010 · 237 citations · Full text
Medicine, Cancer Biology, Oncology +16
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya et al. · Oncogene · 2020 · 186 citations · Full text
Life Sciences, Cancer Biology, Oncology +17
Species differences in response to peroxisome proliferators correlate <i>in vitro</i> with induction of DNA synthesis rather than suppression of apoptosis
Neil H. James, Ruth Roberts · Carcinogenesis · 1996 · 103 citations · Full text
Life Sciences, Toxicology, Apoptosis +13
1–5 of 25